Abstracts/Presentation Description
Qiao-Xin Li1, Colin L Masters1, Steven J Collins1
1The Florey, University of Melbourne
Treatment of Alzheimer’s disease (AD) at an early stage with several monoclonal antibody drugs is approved by the Food and Drug Administration (FDA) and has brought hope for millions of people afflicted by this malady. Measurement with the Elecsys® platform of Aβ42, P-tau181 and T-tau in cerebrospinal fluid (CSF) is approved by FDA to confirm underlying AD neuropathology. This biomarker profile is concordant with amyloid PET imaging, and either can be used to enable access to AD-modifying therapies. We report findings of the National Dementia Diagnostics Laboratory (NDDL) in AD biomarker testing in community settings. We also discuss the utility of AD biomarkers and neurofilament light (NfL) in patients when Creutzfeldt-Jakob disease (CJD) was suspected. Diagnosis of CJD can be challenging due to its non-specific symptoms overlapping with other neurological disorders such as AD. Inclusion of the AD biomarker helps the differential diagnosis of patients presenting with suspected CJD, to improve patient care. We also find elevated concentrations of NfL in CSF from some patients with normal T-tau, indicating that NfL abnormalities undetected by T-tau. Blood biomarkers for AD using automated medical devices are on the path for FDA full approval. NDDL is actively involved in assessing the appropriate use of the blood tests.
1The Florey, University of Melbourne
Treatment of Alzheimer’s disease (AD) at an early stage with several monoclonal antibody drugs is approved by the Food and Drug Administration (FDA) and has brought hope for millions of people afflicted by this malady. Measurement with the Elecsys® platform of Aβ42, P-tau181 and T-tau in cerebrospinal fluid (CSF) is approved by FDA to confirm underlying AD neuropathology. This biomarker profile is concordant with amyloid PET imaging, and either can be used to enable access to AD-modifying therapies. We report findings of the National Dementia Diagnostics Laboratory (NDDL) in AD biomarker testing in community settings. We also discuss the utility of AD biomarkers and neurofilament light (NfL) in patients when Creutzfeldt-Jakob disease (CJD) was suspected. Diagnosis of CJD can be challenging due to its non-specific symptoms overlapping with other neurological disorders such as AD. Inclusion of the AD biomarker helps the differential diagnosis of patients presenting with suspected CJD, to improve patient care. We also find elevated concentrations of NfL in CSF from some patients with normal T-tau, indicating that NfL abnormalities undetected by T-tau. Blood biomarkers for AD using automated medical devices are on the path for FDA full approval. NDDL is actively involved in assessing the appropriate use of the blood tests.
Speaker/Presenting Authors
Authors
Submitting/Presenting Authors
A/Prof Qiao-Xin Li - The Florey, University of Melbourne (Victoria, Australia) , Prof Colin L Masters - The Florey, University of Melbourne (Victoria, Australia) , Prof Steven J Collins - The Florey, University of melbourne (Victoria, Australia)